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OBJECTIVE: Prostate cancer in the United Kingdom is mainly diagnosed from primary care referrals based on national guidelines
published by the Department of Health. Here we investigated the characteristics of cancers detected through the use of these
guidelines.
METHODS: A prospective two-centre study was established to assess men referred from the primary care based on the UK national
guidelines.
RESULTS: The overall cancer detection rate was 43% (169 out of 397) with 15% (26 out of 169) of all cancers metastatic at
presentation. Amongst 50–69-year-old men these rates were 34% (68 out of 200) and 15% (10 out of 68). Only 21% (25 out of
123) of men with local cancers had low-risk disease. In comparison to a historical cohort from 2001 (n¼ 137) we found no overall
differences in rates of metastatic disease, locally advanced tumours, or risk categories. Amongst 50–69-year-old men with local
disease, however, we observed an increase in detection of low-risk cancers in a contemporary cohort (P¼ 0.04). This was primarily
because of the increased detection of low-stage organ-confined tumours in this group (P¼ 0.02).
CONCLUSION: Use of the UK prostate cancer guidelines detects a high proportion of clinically significant cancers. Use of the guidelines
does not seem to have led to an overall change in the clinical characteristics of presenting cancers. There may, however, be a specific
benefit in detecting more low-risk disease in younger men.
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Prostate cancer is the most common malignancy of men in the
United Kingdom and a leading cause of cancer related death.
Screening for prostate cancer using the PSA test has been proposed
as a means of increasing early detection and reducing mortality.
This, however, comes at the cost of significant over-detection with
many men diagnosed with low-risk clinically insignificant disease
(Schro¨der et al, 2009; Sandblom et al, 2011). At the present time
there is no screening programme in the United Kingdom
for prostate cancer and this is unlikely to be introduced with the
currently available PSA test as a tool (Neal et al, 2009).
In the United Kingdom, general practitioners (GP) are the first
physicians to see patients with suspected prostate cancer. Ten
years ago, the Department of Health (DOH) implemented the
National Health Service (NHS) cancer plan, which led to
introduction of guidelines to aid GP referrals to tertiary centres
for suspected cancers (Department of Health, The NHS cancer
plan, 2000). These guidelines were further updated in 2005
following reviews and audits (National Institute for Health and
Clinical Excellence, 2005). In response to these guidelines many
hospitals established rapid access and one stop prostate diagnostic
clinics to see these patients. This mechanism is currently the main
pathway for testing and detection of the prostate cancer in the
United Kingdom. In this study, our aim was to investigate the
presenting characteristics and risk categorisation of prostate
cancers diagnosed using the current version (2005) of the UK
national guidelines.
PATIENTS AND METHODS
A prospective study was set up in two tertiary centres both of
which undertake prostate cancer diagnostic clinics to see patients
referred under the DOH urgent cancer referral guidelines. The
study was performed over two separate time periods and all GP
referrals to these clinics in the time frame were included. Data
collection was prospectively undertaken in Hospital A (n¼ 272,
Addenbrookes Hospital, Cambridge; June–December, 2009) and
Hospital B (n¼ 125, Norfolk and Norwich NHS trust; May—
August, 2010). As this study focused on referrals through the
guidelines, diagnosis through other pathways were excluded. A
prostate cancer diagnosis was made based on the biopsy-proven
tumour or a high index of clinical suspicion warranting initiation
of androgen deprivation therapy. Non-cancer patients were
followed for 12 months after the first clinic appointment to ensure
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that no subsequent prostate cancer diagnosis was made within
1 year. Disease parameters were determined for the group as a
whole and then also defined a priori separately for the 50–69-year
group separately. This was done to specifically assess the impact of
these guidelines on cancer-risk groups in the potential screening
age population as defined by recently published large screening
trials (Schro¨der et al, 2009; Sandblom et al, 2011). All data were
unified in a single database and centrally analysed by an
independent assessor (VG). Risk categories were defined by the
NICE published guidelines for localised prostate cancer. Compar-
ison of tumour characteristics and risk categorisation in Hospital
A (n¼ 103) was then made with a historical cohort of patients seen
in the prostate diagnostic clinics from the same hospital but before
introduction of the 2005 version of the guidelines. To achieve
this, cancer registry data from the Eastern Cancer Registry and
Information Centre was reviewed for all prostate cancers
diagnosed in 2001 in Hospital A and seen only in the prostate
diagnostic clinics (n¼ 137). Men diagnosed through any other
routes were again excluded from this historical analysis cohort.
To facilitate comparison between the groups, data on disease
parameters were standardised for the fifth edition of the TNM
criteria (AJCC comparison guide, fifth vs sixth edition, AJCC, http://
www.cancerstaging.org/products/ajccguide.pdf). Statistical ana-
lysis was performed with Stats Direct software (Cheshire, UK)
using logistic regression, chi-square, and the Mann–Whitney test.
RESULTS
Tumour characteristics and risk stratification of
detected cancers
In all, 169 out of 397 (43%) of the referred men were diagnosed
with prostate cancer from the initial primary care referral (137 by
biopsy and 32 by clinical diagnosis). Out of the 169 patients with
cancer, 26 (15%) had evidence of bone metastasis at the time of
diagnosis (Table 1). A total of 96 out of 169 (55%) had clinical
stage T1–T2 (localised disease) whereas 61 out of 169 (38%) had
T3–T4 (locally advanced disease). Data on stage were not available
in a remaining 12 men. Gleason sum score was assessable in the
137 men who had a diagnostic biopsy (Table 1). There was an even
spread of Gleason grades with 30% of men with Gleason sum 6 and
Gleason 8–10 disease. The remaining men had Gleason 7 cancers.
A similar analysis was next done focusing on the 50–69-year-old
age group. Here, 68 out of 200 (34%) of the men were diagnosed
with prostate cancer with the majority 61 out of 68 (91%)
diagnosed from prostate biopsies. In this group a similar
proportion of men had metastasis at diagnosis (10 out of 68,
15%). The majority had clinically localised disease 49 out of 68
(72%) with 16 out of 68 (28%) with locally advanced disease. When
stratified by grade (n¼ 62), 23 out of 62 (37%) had Gleason sum 6
disease, 26 out of 62 (42%) had Gleason 7 disease, and a minority,
13 out of 62 (21%), had Gleason sum 8–10 disease. We next
assessed the risk categories of men presenting with local disease by
stratifying men according to NICE-defined risk groups. Men who
were clinically diagnosed or had metastasis were necessarily
excluded from this analysis (Table 1). In the evaluated whole
cohort (n¼ 123) the majority of men were categorised as either
intermediate or high risk, 50 out of 123 (41%) and 48 out of 123
(39%), respectively. Only 25 out of 123 (21%) of patients were low
risk. There was no significant difference in the proportions of men
in each risk group when comparison was made between the two
centres (P¼ 0.47, data not shown). In the 50–69-year cohort
(n¼ 58) there were, however, comparatively higher numbers of
men with low-risk disease, 21 out of 58 (36%). A majority of men,
however, still had intermediate-risk disease, 24 out of 58 (41%) and
the smallest group was those with high-risk disease, 13 out of 58
(22%). There was again no difference in risk group distribution in
comparison of the two centres (P¼ 0.73).
Comparison of tumour characteristics with a
historical cohort
We next tested if the guidelines had altered the characteristics of
referred tumours over a period of establishment and familiarity,
and following the revision in 2005 (National Institute for Health
and Clinical Excellence, 2005). These updated guidelines provided
more detailed recommendations compared with the original
guidelines, which only recommended referral for an elevated
age-specific PSA or a PSA 420 in the presence of a malignant
feeling gland or bone pain. The contemporary cohort of men
diagnosed in hospital A were included in this analysis (n¼ 103)
and contrasted with a historical cohort from the same hospital.
In this comparison (Table 2), we found no differences in the rates
of metastasis (18% vs 23%) or clinically advanced disease at
presentation (21% vs 15%) (Table 2). We also found no differences
in the risk categories, Gleason sum scores, clinical stage, or median
presenting PSA between the two cohorts when biopsy diagnosed
men were compared. We then separately considered cancers
detected in the 50–69-year age group in Hospital A between the
contemporary and historical cohorts (Table 3). There was again no
significant difference in metastasis rates or clinically advanced
disease at presentation. Biopsy diagnosed men were next assessed
for the risk type and tumour characteristics. Assessed by risk
categories 23 out of 44 (52%) of men in the 2001 cohort had high-
risk disease whereas only 10 out of 44 (23%) had low-risk disease.
In the 2009 cohort, however, this trend was reversed with 15 out of
35 (43%) of men with low-risk disease and 9 out of 35 (26%) with
high-risk disease (P¼ 0.04) (Table 3). The percentage of men with
intermediate-risk cancers was similar between the two cohorts.
Analysis by Gleason sum score did not identify any significant
change in the distribution amongst different cohorts (P¼ 0.9).
Similarly, there was no difference seen in the median PSA at
diagnosis between cohorts (P¼ 0.1). The most significant differ-
ence, however, was an apparent stage migration in the contem-
porary study cohort. Here, 13 out of 44 (30%) of tumours in
the historical cohort were classed as locally advanced whereas
only 4 out of 35 (11%) of the contemporary cohort were locally
advanced at diagnosis (P¼ 0.02) (Table 3).
Table 1 Characteristics of cancers and risk categories detected in the
whole cohort and in the 50–69-year age group (potential screening age)
Whole
cohort (%)
50–69 year
group (%)
Total cancers detected 169 68
Clinical diagnosis 32 (19) 6 (9)
Biopsy diagnosis 137 (81) 62 (91)
Bone metastasis 26 (15) 10 (15)
Gleason sum score (n¼ 137) (n¼ 62)
p6 41 (30) 23 (37)
7 56 (40) 26 (42)
8–10 40 (30) 13 (21)
Clinical stage
T1–T2 96 (55) 49 (72)
T3–T4 61 (38) 16 (23)
NA 12 (7) 3 (5)
Risk group (localised cancers) (n¼ 123) (n¼ 58)
Low 25 (20) 21 (36)
Intermediate 50 (41) 24 (41)
High 48 (39) 13 (22)
Clinical stage-TNM criteria.
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INTERPRETATION
The intention of this study was to profile the nature of cancers
detected through the national referral guidelines for GP’s
published by the UK DOH. In particular the incidence of
metastasis, clinically advanced disease and in localised disease
the risk categories of cancers. These factors are key determinants
of the treatment needs of the patients. Here we found a high overall
incidence of cancer detection of 43%. These rates, however, are
very similar to data from other centres. Most studies have shown
that while detection of all urological cancers is very variable, there
is a consistently high rate of prostate cancers diagnosed from GP
referrals. Hawary et al (2008) reviewed 170 patients referred for
suspected urological cancer. In this series, 28% of patients were
found to have cancer including 44% of men referred specifically
for suspected prostate cancer. Mathew and Desai (2009) similarly
reported on 400 suspected urological cancer referrals. The authors
reported an overall cancer detection and prostate cancer-specific
detection rate of 23% and 43%, respectively. Allgar et al (2006)
found a 50% detection rate for all urgent referrals with suspected
prostate cancer in one large district hospital trust over a 2-year
period. These data suggest that use of the current guidelines results
in a high rate of prostate cancer detection.
In this study 15% of diagnosed cancers had evidence of
metastasis at presentation. In men with localised disease only a
minority (20%) had low-risk prostate cancer whereas the majority
had intermediate- or high-risk disease that warranted treatment. A
key group for cancer detection is the 50–69-year-old demographic
the so called ‘screening age group’ (Andriole et al, 2009; Schro¨der
et al, 2009). Here, amongst men with localised disease the majority
still had intermediate- or high-risk disease though a proportionally
higher number (one in three) had low-risk disease. These results
suggest that under the current guidelines the majority of detected
cancers are clinically significant and warrant active treatment. Low
risk and indolent is under-represented regardless of the age group
of the patients.
Important reasons for introduction of the guidelines under the
NHS cancer plan were to reduce the times from cancer diagnosis to
treatment and to improve early detection rates. This study could
not comment on any change in times to the prostate cancer
treatment but did ask if more early cancers were being diagnosed.
In comparison with a historical cohort studied in one centre, we
did not observe any appreciable overall difference in the
presenting tumours in terms of the numbers of men with
metastasis or clinically diagnosed cancers. There was also no
difference in tumour histopathological characteristics or overall
risk categories. We acknowledge the weakness that the historical
data were collected retrospectively whereas the contemporary data
were prospective. In this context there could be several sources of
bias, including a greater awareness of the prostate cancer,
increased serendipitous PSA testing, or earlier presentation of
men with lower urinary tract symptoms. Within the limitations
of these possible biases, our findings, however, are similar to
published reports in other tumours, which have also failed to show
improvements in early detection through nationally implemented
cancer guidelines (Debnath et al, 2002; Neal et al, 2007; McKie
et al, 2008; Pencavel et al, 2010). In the present study, however, we
did find that in the 50–69-year age group there was a significant
trend towards detection of more organ confined tumours and as a
consequence an apparent increase in the proportion of low-risk
cancers.
To our knowledge this is the first prospective study to assess the
tumour characteristics of prostate cancers detected through
the UK national cancer referral guidelines. Our results suggest
that the use of the guidelines have not led to any overall
improvement in early detection of prostate cancer and most men
will present with advanced disease or disease that warrants active
treatment. Within the limits of our small cohort size there is
preliminary evidence, however, that younger men may benefit
most from these guidelines with increased proportions of men with
low-risk disease because of a stage migration effect.
As the introduction of a screening programme in the United
Kingdom is not imminent, GP referrals based on these guidelines
will continue to be the primary route for men to be identified for
investigation of suspected prostate cancer. Based on these
preliminary results we do not currently advocate any change in
Table 2 Comparison of characteristics of detected cancers in the
prostate diagnostic clinics between the current cohort and a historical
cohort from 2001 in Hospital A for men of all ages
2009
cohort (%)
(n¼ 103)
2001
cohort (%)
(n¼ 137) P-value
Metastasis 19 (18) 31 (23) 0.4
Clinical diagnosis 22 (21) 21 (15) 0.2
Risk group (localised cancers) (n¼ 74) (n¼ 100)
Low 21 (28) 22 (22)
Intermediate 18 (24) 25 (25)
High 35 (48) 53 (53) 0.6
Gleason sum
p6 33 (45) 48 (48)
7 21 (28) 29 (29)
8–10 20 (27) 23 (23) 0.1
Clinical stage
T1–T2 58 (78) 74 (74)
T3–T4 16 (22) 26 (26) 0.5
PSA mg l1
Median (range) 10.6 (2.8–82) 11.4 (3.9–424) 0.1
Po0.05 taken as statistically significant.
Table 3 Comparison of characteristics of detected cancers in the
prostate diagnostic clinics between the current cohort and a historical
cohort from 2001 in Hospital A for men aged 50–69 years
2009
cohort (%)
(n¼ 43)
2001
cohort (%)
(n¼ 52) P-value
Metastasis 8 (18) 7 (13) 0.7
Clinical diagnosis 4 (9) 1 (2) 0.1
Risk group (localised cancers) (n¼ 35) (n¼ 44)
Low 15 (43) 10 (23)
Intermediate 11 (31) 11 (25)
High 9 (26) 23 (52) 0.04
Gleason sum
p6 18 (51) 23 (52)
7 10 (29) 13 (30)
8–10 7 (20) 8 (18) 0.9
Clinical stage
T1–T2 31 (89) 31 (70)
T3–T4 4 (11) 13 (30) 0.02
PSA mg l1
Median (range) 7.7 (2.8–45.8) 10.5 (3.9–201) 0.1
Po0.05 taken as statistically significant.
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this practise. Indeed the current guidelines do lead to a high rate of
cancer detection as shown in this and other publications. These
findings, however, do support the notion of further exploration of
the risk profiles of presenting cancers by undertaking multi-centre
prospective studies evaluating the cancer characteristics detected
through urgent cancer referrals and stratified by age. This could
then lead to an informed discussion of how the guidelines can be
improved or perhaps focused on particular patient age groups.
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